Gastroprotective therapy and risk of gastrointestinal ulcers: Risk reduction by COX-2 therapy

Journal of Rheumatology

Volumn 29, Issue 3, 2002, Pages 467-473

  Wolfe, Frederick ^a   Anderson, Janice ^a   Burke, Thomas A ^a   Arguelles, Lester M ^a   Pettitt, Dan ^a  

^a ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

Author keywords

Cyclooxygenase 2; H2 blockers; Proton pump inhibitors; Risk; Upper gastrointestinal ulcers

Indexed keywords

ANTACID AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FENOPROFEN; FLURBIPROFEN; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOPROFEN; LANSOPRAZOLE; MECLOFENAMIC ACID; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXAPROZIN; PIROXICAM; PROTON PUMP INHIBITOR; ROFECOXIB; SALSALATE; SUCRALFATE; SULINDAC; TOLMETIN;

ADULT; AGED; ARTHRITIS; ARTICLE; DIGESTIVE SYSTEM ULCER; DISEASE MARKER; DRUG BINDING; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DUODENUM ULCER; ENZYME INHIBITION; ENZYME SPECIFICITY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTON TRANSPORT; STOMACH PROTECTION; ULCER HEALING; VALIDATION PROCESS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; FEMALE; GASTROINTESTINAL AGENTS; HISTAMINE H2 ANTAGONISTS; HUMANS; INCIDENCE; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PEPTIC ULCER; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTON PUMPS; QUESTIONNAIRES; RHEUMATIC DISEASES; RISK FACTORS;

EID: 0036198144     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
2. Antiinflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
3. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised doubleblind comparison
4. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor
5. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
6. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study
7. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study
8. The epidemiology of nonsteroidal anti-inflammatory drugs
9. Non-steroidal anti-inflammatory drug associated ulcer - Epidemiology, causation and treatment
10. Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis
11. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta
12. NSAIDs increase risk of gastrointestinal bleeding in primary care patients with dyspepsia
13. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons
14. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. A randomized, double-blind, placebo- controlled trial
15. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models
16. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs - A metaanalysis
17. Corticosteroid use and peptic ulcer disease: Role of nonsteroidal antiinflammatory drugs
18. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury
19. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: A prospective 13 year study of 2131 patients
20. Peptic ulcer bleeding: Accessory risk factors and interactions with nonsteroidal antiinflammatory drugs
21. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy
22. Superiority of lansoprazole vs ranitidine in healing nonsteroidal antiinflammatory drug-associated gastric ulcers: Results of a double-blind, randomized, multicenter study
23. Prevention of chronic NSAID induced upper gastrointestinal toxicity
24. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID Associated Ulcer Treatment (ASTRONAUT) Study Group
25. Famotidine for healing and maintenance in nonsteroidal antiinflammatory drug-associated gastroduodenal ulceration
26. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs
27. The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: Cohort study
28. NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997. Arthritis, rheumatism, and aging medical information system
29. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group
30. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 agents: Quantitative assessment of channeling bias and confounding by indication in 6689 RA and OA patients
31. Channeling bias in the interpretation of drug effects
32. Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin
33. Assessment and control for confounding by indication in observational studies
34. Confounding by indication: An example of variation in the use of epidemiologic terminology
35. Confounding and indication for treatment in evaluation of drug treatment for hypertension
36. Confounding by indication and channeling over time: The risks of beta 2-agonists
37. The National Rheumatic Disease Data Bank: Case mix and severity characteristics of patients in rheumatological practice
38. Disease modifying antirheumatic drugs (DMARD) and DMARD combination use by 3604 patients of 303 US rheumatologists
39. Gastrointestinal symptoms and health related quality of life in patients with arthritis
40. The longterm outcomes of rheumatoid arthritis. Work disability: A prospective 18 year study of 823 patients
41. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis
42. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer - A randomized, controlled trial
43. The dimensions of health outcomes: The Health Assessment Questionnaire, disability and pain scales
44. Measurement of patient outcome in arthritis
45. The MOS 36-item short-form health survey SF-36. 1. Conceptual framework and item selection
46. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study